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A B S T R A C T
Background
Every day children and adults die from acute community-acquired bacterial meningitis, particularly in low-income countries, and
survivors risk deafness, epilepsy and neurological disabilities. Osmotic therapies may attract extra-vascular fluid and reduce cerebral
oedema, and thus reduce death and improve neurological outcomes.
This is an update of a Cochrane Review first published in 2013.
Objectives
To evaluate the effects of osmotic therapies added to antibiotics for acute bacterial meningitis in children and adults on mortality,
deafness and neurological disability.
Search methods
We searched CENTRAL (2017, Issue 1), MEDLINE (1950 to 17 February 2017), Embase (1974 to 17 February 2017), CINAHL
(1981 to 17 February 2017), LILACS (1982 to 17 February 2017) and registers of ongoing clinical trials (ClinicalTrials.com, WHO
ICTRP) (21 February 2017). We also searched conference abstracts and contacted researchers in the field (up to 12 December 2015).
Selection criteria
Randomised controlled trials testing any osmotic therapy in adults or children with acute bacterial meningitis.
Data collection and analysis
Two review authors independently screened the search results and selected trials for inclusion. Results are presented using risk ratios
(RR) and 95% confidence intervals (CI) and grouped according to whether the participants received steroids or not. We used the
GRADE approach to assess the certainty of the evidence.
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Main results
We included five trials with 1451 participants. Four trials evaluated glycerol against placebo, and one evaluated glycerol against 50%
dextrose; in addition three trials evaluated dexamethasone and one trial evaluated acetaminophen (paracetamol) in a factorial design.
Stratified analysis shows no effect modification with steroids; we present aggregate effect estimates.
Compared to placebo, glycerol probably has little or no effect on death in people with bacterial meningitis (RR 1.08, 95% CI 0.90 to
1.30; 5 studies, 1272 participants; moderate-certainty evidence), but may reduce neurological disability (RR 0.73, 95% CI 0.53 to 1.00;
5 studies, 1270 participants; low-certainty evidence).
Glycerol may have little or no effect on seizures during treatment for meningitis (RR 1.08, 95% CI 0.90 to 1.30; 4 studies, 1090
participants; low-certainty evidence).
Glycerol may reduce the risk of subsequent deafness (RR 0.64, 95% CI 0.44 to 0.93; 5 studies, 922 participants; low to moderate-
certainty evidence).
Glycerol probably has little or no effect on gastrointestinal bleeding (RR 0.93, 95% CI 0.39 to 2.19; 3 studies, 607 participants;
moderate-certainty evidence). The evidence on nausea, vomiting and diarrhoea is uncertain (RR 1.09, 95% CI 0.81 to 1.47; 2 studies,
851 participants; very low-certainty evidence).
Authors’ conclusions
Glycerol was the only osmotic therapy evaluated, and data from trials to date have not demonstrated an effect on death. Glycerol may
reduce neurological deficiency and deafness.
P L A I N L A N G U A G E S U M M A R Y
Osmotic therapies added to antibiotics for acute bacterial meningitis
What is the aim of this review?
The aim of this Cochrane Review is to collect and analyse trials evaluating osmotic therapies given orally or intravenously to people
with acute bacterial meningitis. Cochrane authors collected and analysed all relevant studies to answer this question; they found five
relevant studies.
Key messages
Giving glycerol, an osmotic diuretic, probably has little or no effect on death (moderate-certainty evidence), but may reduce subsequent
deafness (moderate-certainty evidence) or neurological disability (low-certainty evidence). The evidence is current to 17 February 2017.
What was studied in the review?
In meningitis, the cerebrospinal fluid that surrounds the brain and spinal cord is infected, usually as a result of spread from the blood.
Any form of meningitis can result in death or severe disability, but acute bacterial meningitis is rapidly fatal without treatment. Even
with antibiotics, 10% to 15% of children with bacterial meningitis die in high-income countries with much higher rates in low-income
settings. The infection causes the brain to swell, and this is thought to contribute to death and to long-term brain damage in survivors.
Osmotic therapies increase the concentration of the blood by exerting an osmotic pressure across a semi-permeable membrane (such as
a cell wall or blood vessel lining in the brain). This draws water from the brain into the blood, thereby reducing pressure in the brain.
Potentially osmotic therapies could increase the rate of survival, or they could do harm.
What are the main results of the review?
We included five trials that compared glycerol with placebo in a total of 1451 patients with bacterial meningitis. In the studies steroids
were often given as well, but this did not appear to modify any of the effects seen with glycerol.
This review detected no benefit from glycerol relating to death. There appeared to be marginal protection against deafness and against
neurological disability. No effect on epileptic seizures at follow-up was noted. Glycerol was not associated with any severe adverse effects.
The number of trials included was small and only two tested a large number of participants. All trials were from different healthcare
settings and examined either adults or children.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Glycerol for acute bacterial meningitis
Patient or population: children and adults with acute bacterial meningit is
Settings: Finland, India, South America, Malawi
Intervention: glycerol with or without steroids compared with placebo. All part icipants received broad-spectrum antibiot ics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Glycerol
Death 19 per 100 21 per 100
(17 to 25)
RR 1.08
(0.90 to 1.30)
1272
(5 studies)
⊕⊕⊕©
Moderate1,2,3,4
Downgraded for impre-
cision.
Glycerol probably has
lit t le or no ef fect on
death
Neurological disability 9 per 100 6 per 100
(5 to 9)
RR 0.73
(0.53 to 1.00)
1270
(5 studies)
⊕⊕©©
Low1,3,4,5
Downgraded for impre-
cision and inconsis-
tency.
Glycerol may reduce
disability
Seizures 32 per 100 35 per 100
(29 to 42)
RR 1.08
(0.90 to 1.30)
1090
(4 studies)
⊕⊕©©
Low1,3,4,6
Downgraded for incon-
sistency and impreci-
sion.
Glycerol may have lit t le
or no ef fect on seizures
Hearing loss 16 per 100 10 per 100
(7 to 15)
RR 0.64
(0.44 to 0.93)
922
(5 studies)
⊕⊕⊕©
Moderate 1,2,3,7
Downgraded for impre-
cision.
Glycerol probably re-
duces hearing loss
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Adverse effects: nau-
sea, vomiting, diar-
rhoea
47 per 100 51 per 100
(38 to 69)
RR 1.09
(0.81 to 1.47)
851
(2 studies)
⊕©©©
Very low1,3,4,8,9
Downgraded for serious
inconsistency and im-
precision.
The ef fect of glycerol on
adverse events: nausea,
vomit ing and diarrhoea
is uncertain
Adverse effects: gas-
trointestinal bleeding
3 per 100 3 per 100
(13 to 8)
RR 0.93
(0.39 to 2.19)
607
(3 studies)
⊕⊕⊕©
Moderate1,2,3,4
Downgraded for impre-
cision.
Glycerol probably has
lit t le or no ef fect on ad-
verse events: gastroin-
test inal bleeding
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval (CI)) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval
RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
1No serious risk of bias: allocat ion concealment was adequate in four trials and unclear (not reported) in one trial.
2Not downgraded for inconsistency.
3Not downgraded for indirectness. The f ive trials were conducted in Finland, Malawi, India and South America. Four were in
children and one in adults. All included pat ients with suspected meningit is and cerebrospinal f luid (CSF) changes suggest ive
of bacterial infect ion.
4Downgraded by one level for imprecision: the 95% CI includes what might be a clinically important harm and no ef fect with
glycerol.
5Downgraded by one level for inconsistency: in the Finnish trial the risk of neurological sequelae was reduced with glycerol
(RR 0.50, 95% CI 0.32 to 0.78, N = 329), but this was not found in the other studies and the meta-analysis did not detect a
dif ference (I² = 59%).
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6Downgraded by one level for inconsistency: in the trial with adults the risk of seizures was higher with glycerol (RR 1.62, 95%
CI 1.18 to 2.23, N = 250), but this was not found in the other studies and the meta-analysis did not detect a dif ference (I² =
62%).
7Downgraded by one level for imprecision: the number of pat ients with reported hearing loss was low in these studies and
the 95% CI includes both no ef fect and what might be a clinically important benef it with glycerol. Larger studies would be
necessary to have full conf idence in this ef fect.
8Another two trials reported on this outcome but the results could not be added to the meta-analysis; one reported more
cases of vomit ing with glycerol and the other that the incidence of vomit ing was ‘‘sim ilar’’ in the treatment groups.
9Downgraded by two levels for inconsistency: in the South American and Finnish trials the risk of adverse ef fects was
increased with glycerol, but this was not found in the Malawi and India trials, and the meta-analysis did not detect a dif f erence
(I² = 79%).
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B A C K G R O U N D
Description of the condition
Community-acquired acute bacterial meningitis is a devastating
infection with associated rates of death and disability that have
changed little over the last 10 to 15 years. In high-income coun-
tries, 5% to30%of adult patients die, rising to 50% to60% in low-
income countries, despite highly effective antibiotics against the
causative pathogens (de Gans 2002; Nguyen 2007; Scarborough
2007). The high mortality is predominately seen in Streptococ-
cus pneumoniae (S pneumoniae) infections; meningitis caused by
Neisseria meningitidis (Nmeningitidis) carries a lower mortality. In
children, a wider range of pathogens are noted and the case fatality
rate is lower (Harnden 2006; Molyneux 2006; Pelkonen 2009;
Peltola 2009; Roine 2009). Nevertheless, some survivors develop
neurological problems that may be permanent. The most com-
mon meningitis sequelae are deafness, epilepsy and poor cognitive
development (Molyneux 2002; Nguyen 2007; van de Beek 2009),
thought to be caused by infection-induced inflammation, throm-
bosis and brain oedema (swelling). The outcome from bacterial
meningitis is influenced by the pathogen, the geographical area,
the patient’s access to healthcare and the quality of the healthcare
system. There are very few data on risk factors for poor outcomes
in low-income countries. However, anaemia and delayed presen-
tation to hospital are probably important (McCormick 2012;
Sudarsanam 2017). HIV may influence outcomes but the role of
the virus in pathogenesis is not yet clearly understood (Domingo
2009). High mortality rates, despite effective antibiotics, have led
investigators to try and minimise neurological inflammation with
adjunctive therapies.
Increasing understanding of the pathways of cerebral inflamma-
tion in meningitis has led several investigators to try treatments
that aim to reduce brain oedema and inflammation and improve
brain perfusion. The intervention most extensively tested in clin-
ical trials has been corticosteroids. A Cochrane Review shows a
mortality benefit in adults in Europe with meningitis due to S
pneumoniae and an overall reduction in deafness in adults and
children (Brouwer 2015). Another systematic review of individual
patient data from five randomised studies suggests that the effect
of dexamethasone on outcomes for bacterial meningitis in these
countries is limited to reducing the incidence of hearing loss in
survivors (van de Beek 2010). A long-held concern exists over ex-
cessive fluids contributing to brain oedema; a further Cochrane
Review suggests that judicious fluid resuscitation guided by the
clinical condition is appropriate tomaximise brain perfusion with-
out contributing to brain oedema (Maconochie 2016).
Description of the intervention
Osmotic therapies work by increasing the concentration of the
blood. They exert an osmotic pressure across a semi-permeable
membrane (such as a cell wall or blood vessel lining in the brain),
which draws water from the brain into the blood and reduces
pressure in the brain. This is theoretically advantageous if brain
swelling is causing reduction in brain function.
Osmotic therapies have long been used in acute brain trauma
(BTF 2000), and their use has been postulated in other forms of
acute brain injury, particularly stroke (Bereczki 2007; Yu 1992;
Yu 1993) and cerebral malaria (Namutangula 2007; Okoromah
2011). Mannitol and hypertonic saline are the most commonly
used osmotic therapies (Wakai 2013), but glycerol, sorbitol and
sodium lactate have also been investigated (Righetti 2004; Stoll
1998). Details of all these therapies are reported in Table 1. Glyc-
erol has been studied in animals with meningitis, where no ef-
fect was noted. Conclusions from these studies are limited by the
applicability of animal models of meningitis, where set doses of
pathogenic bacteria are introduced directly into the animal’s cen-
tral nervous system, to the complex host pathogen interactions in
human disease (Blaser 2010; Schmidt 1998). The excellent safety
profile of glycerol in previous studies (Righetti 2004), combined
with its low cost and easy administration and availability, has led
investigators to look for its efficacy as an adjuvant treatment in
acute bacterial meningitis in both adults and children, particularly
in low-income countries.
How the intervention might work
All osmotic therapies have slightly different and poorly understood
mechanisms of action. The osmotic drug’s mechanism of action
causes dehydration of central nervous system (CNS) cells, lower-
ing intracranial pressure (ICP). However this effect may only be
temporary and lead to a rebound phenomenon where cells subse-
quently draw in too much water, increasing the oedema.Mannitol
has this mechanism of action but acts primarily by erythrocyte
deformity through increases in intravascular water, allowing in-
creased tissue oxygenation in the CNS. Mannitol produces a large
diuresis through this effect, which causes a reflex cerebral vasocon-
striction, temporarily reducing ICP. However, there is a significant
risk of subsequent rebound raised ICP and mannitol is now used
sparingly due to this concern. The main mechanism of action of
glycerol in humans is unknown but there are some data to suggest
that the addition of glycerol in meningitis could potentially im-
prove cerebral blood flow and metabolism (Mathew 1972; Meyer
1972). Glycerol also has a mild effect on serum osmolality (Singhi
2008).
Hypertonic saline and sodium lactate appear to have direct osmotic
actions on cells and they do not cause diuresis. These drugs may
therefore be better than mannitol in reducing ICP (Ichai 2009).
Osmotic diuretics such as mannitol and sorbitol could potentially
also have a clinical benefit in meningitis through reduction in ICP
but may risk volume depletion in the febrile patient. All osmotic
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therapies ideally require an intact blood brain barrier to exert their
effects. Bacterial meningitis causes disruption of the barrier due
to intense inflammation in the subarachnoid space and therefore
it cannot be assumed that osmotic therapies would be beneficial.
Table 1 gives details of all the properties of currently available
osmotic therapies.
Why it is important to do this review
To date, there have been a few placebo-controlled studies using
osmotic therapies in meningitis published in different settings in
children and adults. A systematic review and meta-analysis would
help to decide if these studies have demonstrated clinical bene-
fit either by improvement in mortality or long-term neurological
disabilities from the use of these treatments. This review aimed
to encompass all types of osmotic therapies to investigate whether
the principle of osmotic pressure change in the CNS is of benefit
in people with meningitis and to demonstrate whether osmotic
therapies should be recommended in principle, or if a particular
therapy should be recommended in the treatment of acute bacte-
rial meningitis.
O B J E C T I V E S
To evaluate the effects of osmotic therapies added to antibiotics
for acute bacterial meningitis in children and adults on mortality,
deafness and neurological disability.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adults and children diagnosed with acute community-acquired
bacterial meningitis, as defined by the trial authors, on the basis of
cerebrospinal fluid (CSF) culture, white cell count, biochemical
composition and clinical presentation.
Types of interventions
Intervention: osmotic therapy, including at least one of the fol-
lowing: orally administered glycerol, intravenous (IV) hypertonic
saline, sodium lactate and osmotic diuretics including IV manni-
tol and sorbitol.
Control: standard IV therapy or matched placebo.
All participants received broad-spectrum intravenous antibiotic
treatment.
Types of outcome measures
Primary outcomes
1. All-cause mortality.
Secondary outcomes
1. Residual neurological deficit at the end of the follow-up
period, including focal neurological deficit, epilepsy and
deafness. Deafness was defined as hearing loss greater than 40
decibels bilaterally.
2. Epilepsy/seizures.
3. Deafness (hearing loss greater than 40 decibels bilaterally).
4. Adverse effects.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL 2017, Issue 1), part of the Cochrane Library,
www.thecochranelibrary.com (accessed 17 February 2017), which
contains the Acute Respiratory InfectionsGroup’s SpecialisedReg-
ister, MEDLINE (Ovid) (1950 to 17 February 2017), Embase
(Elsevier) (1974 to 17 February 2017), LILACS (BIREME) (1982
to 17 February 2017) andCINAHL (Ebsco) (1981 to 17 February
2017).
We used the search terms described in Appendix 1 to searchMED-
LINE andCENTRAL.We combined theMEDLINE search strat-
egy with the Cochrane Highly Sensitive Search Strategy for identi-
fying randomised trials inMEDLINE: sensitivity-maximising ver-
sion (2008 revision); Ovid format (Lefebvre 2011). We adapted
the search strategy to search Embase (Appendix 2), CINAHL (Ap-
pendix 3) and LILACS (Appendix 4).
Searching other resources
We searched the following clinical trials registers on 21 February
2017.
1. ClinicalTrials.gov (www.clinical trials.gov) (Appendix 5).
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2. World Health Organization International Clinical Trials
Registry Portal (WHO ICTRP, www.who.int/ictrp/en/)
(Appendix 6).
For previous versions of this review we also searched conference
abstracts and contacted researchers in the field (to 12 December
2015).
Data collection and analysis
Selection of studies
One author (EW) screened all search results (title and abstract) and
selected relevant studies according to the review inclusion criteria.
Two authors (EW, KA) screened all selected studies by reading
the published full text to ensure each study met the inclusion
criteria. The same two authors then agreed which studies were
to be included in the review. We emailed trial authors to clarify
duplication and study numbers.
Data extraction and management
Two review authors (EW, KA) independently extracted all data
from the selected studies using a data extraction form. We dis-
cussed all trial data, which were then included only when the data
matched those extracted by both review authors. We contacted
one trial author regarding duplication and we excluded one study
from the analysis as a result. No further discrepancies arose during
data extraction. We entered data for analysis using RevMan 5.3
software (Review Manager 2014).
Assessment of risk of bias in included studies
The data extraction form included a ’Risk of bias’ collection tool.
Two review authors (EW, KA) independently judged the potential
risk of bias for each included study as low, uncertain or high for the
following parameters (Higgins 2011). Both review authors then
discussed and agreed the final judgements. One review author
(EW) synthesised these judgements into a standard ’Risk of bias’
table for each study. See Characteristics of included studies.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding.
4. Incomplete outcome data.
5. Selective reporting of outcome data.
6. Other identified areas of bias particular to that study (e.g. if
the principal investigator was employed by the pharmaceutical
company manufacturing the drug under investigation, or if the
study is sponsored by a pharmaceutical company).
Measures of treatment effect
The primary outcome of this review was binary and the studies
included were all RCTs, therefore we used the risk ratio (RR) as
the most appropriate statistical tool to express the results of the
treatment effect in a meta-analysis. We displayed the results as
forest plots.
All included studies had outcomes defined by the trial authors
using standardised measurements. We counted hearing loss of
greater than 40 decibels (dB) as significant where measured. If a
formal neurological score was used to define neurological disabil-
ity we used this. However, where only a description was given, we
counted a described deficit that results in the participant not being
able to work or attend school as significant. As the number of stud-
ies was small we were not able to analyse mortality by continental
geographical area and resource setting as secondary outcomes, as
planned in the protocol.
Due to the small number of studies retrieved, we were unable
to group results for both primary and secondary outcomes by
the follow-up period: acute phase, less than three months since
inclusion in the study and longer-term up to one year of follow-
up.
Unit of analysis issues
We did not anticipate any cluster-randomised trials on this topic.
However, within the trials included, a four parallel-arm design was
employed. We separated data into groups comparing the inter-
vention alone with placebo, and the intervention plus a second
intervention with the second intervention alone. These results are
expressed in Analysis 1.1 and Analysis 1.4.
Dealing with missing data
We found some relevant data to be missing from Kilpi 1995,
Sankar 2007 and Molyneux 2014. We contacted the authors for
clarification or additional data. Molyneux provided information
and data; we did not receive responses from Kilpi or Sankar.
Assessment of heterogeneity
We intended to use the I² statistic and to explore explanations for
heterogeneity by subgroup analysis as outlined in the protocol,
but the data were insufficient.
Assessment of reporting biases
We assessed each study for reporting bias. Where it was suspected
that selected results had been presented, we contacted the authors
for clarification (see Dealing with missing data).
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Data synthesis
We entered all extracted data into RevMan 5.3 (Review Manager
2014) and performed all analyses using this software.We expressed
all results using forest plots. We used a fixed-effect model for anal-
ysis and found minimal heterogeneity between the studies. We
repeated the analyses using a random-effects model where hetero-
geneity was detected. We present the results from the fixed-effect
model. Where disagreement in effect size was determined between
the fixed-effect and random-effects models, we present data from
both models.
GRADE and ’Summary of findings’ table
We created Summary of findings for the main comparison using
the following outcomes: death, neurological disability, seizures,
hearing loss and adverse effects.We used the five GRADE consid-
erations (study limitations, consistency of effect, imprecision, in-
directness and publication bias) to assess the quality of evidence as
it related to the studies that contributed data to the meta-analyses
for the prespecified outcomes (Atkins 2004).We used themethods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) using GRADEpro GDT software (GRADEpro
GDT 2014). We justified all decisions to downgrade or upgrade
the quality of studies in footnotes, and made comments to aid
readers’ understanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
We obtained 31 records from the 2017 update search; two dupli-
cates were excluded. We assessed 29 records and could exclude 19
titles and abstracts. We obtained five full texts and excluded four.
We included one new study in this update (Molyneux 2014).
We screened a total of 752 abstracts following the initial search in
November 2010. Further records were screened following update
searches inNovember 2012 (35 records from electronic databases),
November 2014 (24 records) and February 2017 (24 records from
electronic databases and five records from trials databases). This
resulted in 840 screened abstracts in total over the history of this
review including updates. See Figure 1.
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Figure 1. Study screening flow diagram
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Included studies
Five trials, published in eight trial reports, with a total of 1451
participants met the inclusion criteria (Ajdukiewicz 2011; Kilpi
1995; Molyneux 2014; Peltola 2007; Sankar 2007). Molyneux
2014 was added at this update and included 181 participants.
We extracted no data from a companion paper to Sankar 2007;
it reported osmolarity data for a subset. We similarly extracted
no data from a companion paper to Peltola 2007; it reported on
deafness in more detail.
All included studies tested glycerol compared to matched placebo,
with some studies including a dexamethasone arm and one study
an acetaminophen (paracetamol) arm.
Study funding sources
Four studies were funded by research foundations (Ajdukiewicz
2011; Kilpi 1995;Molyneux 2014; Peltola 2007) and of these, two
studies were also partially funded by the pharmaceutical industry (
Kilpi 1995; Peltola 2007). One study reported no funding (Sankar
2007).
Participants
Four trials were conducted in children aged under 16 years (Kilpi
1995; Molyneux 2014; Peltola 2007; Sankar 2007) and one in
adults and adolescents aged over 14 years (Ajdukiewicz 2011).
Interventions
All included studies used oral glycerol as the primary intervention.
The potential mechanism of action of glycerol is detailed in Table
1. The four trials in children evaluated glycerol alone, dexametha-
sone alone, glycerol combined with dexamethasone and glycerol
combined with paracetamol. These studies used intravenous (IV)
placebo to ’blind’ the dexamethasone treatment group.Noplacebo
for oral glycerol was used in Kilpi 1995 and Sankar 2007. Peltola
2007 and Molyneux 2014 used oral carboxymethylcellulose as a
placebo for glycerol.
The adult study used 50% dextrose as an oral placebo agent to
compare to glycerol diluted inwater or 50%dextrose (Ajdukiewicz
2011).
Location
Kilpi 1995 took place in Finland, Peltola 2007 in South America
(multiple sites), Sankar 2007 in India and both Ajdukiewicz 2011
and Molyneux 2014 in Malawi.
Outcomes
Death was the primary outcome in all included studies.
In Peltola 2007, we noted different results in tables 2 and 3. As
there appeared to be exclusions in table 3, we used the data from
table 2, which appeared to be intention-to-treat.
Excluded studies
We excluded 13 studies (14 records). We found that 11 studies,
which each used or mentioned the use of osmotic therapies, were
not randomised controlled trials (RCTs) and these were excluded.
Reasons for exclusion were as follows:
• five studies were not randomised trials;
• four were review articles;
• one was a systematic review (we screened the reference list
and found no new studies to include in our review); and
• one was a letter replying to an editorial comment.
We also excluded one study that included children with acute
central nervous system infections and raised intracranial pressure
(ICP) randomised to receive cerebral perfusion pressure-targeted
therapy or intracranial pressure-targeted therapy (Kumar 2014);
and one study that was a registered trial record (CTRI/2015/04/
005668). The trial registry stated that it had been suspended and
thiswas confirmedwith the trialists. See Figure 1 for a flowdiagram
of the study selection process.
Studies awaiting classification
There are currently no studies awaiting classification.
Ongoing studies
We did not identify any ongoing studies.
Risk of bias in included studies
Risk of bias was mostly low; 70% of our judgements were of low
risk of bias (see Figure 2). See Figure 3 for our judgements for each
risk of bias item for each included study.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
13Osmotic therapies added to antibiotics for acute bacterial meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Allocation
The risk of bias was low for random sequence generation across
all studies. Allocation concealment was adequately described for
all but one study (Molyneux 2014), which we judged at unclear
risk of bias (Figure 2 and Figure 3). We judged Peltola 2007 at
unclear risk of allocation bias due to changes in the protocol that
occurred during the study, a change from two dexamethasone to
one placebo to one dexamethasone to one placebo, as reported by
a meta-analysis of individual patient data testing dexamethasone
compared to placebo for bacterial meningitis (van de Beek 2010).
Blinding
The risk of bias was low for blinding across four studies.We judged
Kilpi 1995 at high risk of performance and detection bias, as no
details of any concealment were given, so we assumed that the allo-
cations were not blinded (Figure 2). The review authors requested
clarification from the authors of Kilpi 1995 but no response has
been received.
Incomplete outcome data
Four studies reported complete data and we judged them to have
a low risk of attrition bias. Data on two participants were missing
from Kilpi 1995 and we judged this study to have a high risk of
attrition bias.
Selective reporting
We judged Ajdukiewicz 2011 and Peltola 2007 to have a low risk
of reporting bias as all data appeared to be presented clearly and
completely. Kilpi 1995 presented selected data as there was signif-
icant attrition bias, so we judged it to have a high risk of reporting
bias. We judged Sankar 2007 to have an unclear risk of reporting
bias as neither adverse effects nor time of stopping treatment were
presented. Kilpi 1995 did not respond to our request for data on
all enrolled trial participants.
Other potential sources of bias
No trials were sponsored by pharmaceutical companies, nor were
the authors declared to have conflicts of interest. Peltola 2007 was
partly funded by a pharmaceutical company, which supplied the
dexamethasone for the trial but not the glycerol, so we did not
judge this to have a significant bias effect on this analysis. Kilpi
1995 was also partially funded by a pharmaceutical company and
we judged the risk of bias as unclear.
Effects of interventions
See: Summary of findings for the main comparison Glycerol
for acute bacterial meningitis
We included five trials, all evaluating glycerol. Four of the trials
had four arms, which also compared glycerol plus dexamethasone
with dexamethasone alone or glycerol plus paracetamol and parac-
etamol alone.
We carried out the initial analysis comparing participants who re-
ceived glycerol or placebo only, or glycerol with paracetamol or
placebo with paracetamol, labelled ’no steroids’. We carried out
a subgroup analysis with the remaining trial participants who re-
ceived either glycerol plus dexamethasone or dexamethasone plus
placebo, labelled ’with steroids’. All trial participants received the
antibiotic ceftriaxone, so no antibiotic subgroup analysis was nec-
essary. Due to the small number of included studies, a subgroup
analysis of paediatric data was not possible.
Primary outcome
All-cause mortality
In the adult study, there weremore deaths in the glycerol group and
this led to the study being stopped by the data monitoring com-
mittee (risk ratio (RR) 1.30, 95% confidence interval (CI) 1.04
to 1.62) (Ajdukiewicz 2011). None of the other studies detected
harm with glycerol and the meta-analysis did not detect an effect
on mortality (RR 1.08, 95% CI 0.90 to 1.30, 1272 participants,
5 trials, I² = 17%, Analysis 1.1, moderate-certainty evidence). The
stratified analysis found no significant difference whether dexam-
ethasone was administered or not.
Secondary outcomes
1. Residual neurological deficit at the end of the follow-up
period
Overall, a slight reduction (54/644 cases) in neurological disability
was reported in the glycerol group compared with the placebo
group (77/626) (RR0.73, 95%CI0.53 to 1.00, 1270participants,
5 trials, I² = 50%, Analysis 1.2, low-certainty evidence). The effect
size was further reduced using the random-effectsmodel (RR0.70,
95% CI 0.38 to 1.27). Little or no difference was detected in the
subgroup of participants who received steroids (RR 0.82, 95% CI
0.38 to 1.77, 419 participants, 3 trials, I² = 25%).
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2. Epilepsy/seizures
Convulsions on admission and during treatment were reported in
all studies but none reported data for persistent epileptic seizures
post discharge. In the adult study, the risk of seizures was higher
with glycerol (RR1.62, 95%CI 1.18 to 2.23) (Ajdukiewicz 2011).
However, this was not found in the other studies and the meta-
analysis did not detect a difference (RR1.08, 95%CI 0.90 to 1.30;
1090 participants, 4 trials, I² = 54%, Analysis 1.3, low-certainty
evidence).
3. Deafness
Fewer surviving participants given glycerol were reported as deaf
at four to eight weeks of follow-up compared to placebo (RR 0.64,
95% CI 0.44 to 0.93; 5 trials, 922 participants, I² = 7%, Analysis
1.4,moderate-certainty evidence). Using the random-effects model,
the estimate of the effect size of glycerol on deafness was slightly
lower (RR 0.67, 95% CI 0.44 to 1.01).
Adverse effects
Neither glycerol nor dexamethasone were associated with signifi-
cant adverse effects in the included studies but systematic record-
ing of adverse events was not reported. Only Ajdukiewicz 2011
reported on serious adverse events (SAEs). One SAE was reported
each in glycerol and placebo arm participants, both considered
possibly due to the study drug but the researchers reported that the
most likely diagnosis for both participants (HIV-positive adults in
Malawi) was a major cerebrovascular event secondary to meningi-
tis.
Common adverse effects were nausea and vomiting; there were
also small numbers of cases of gastrointestinal bleeding.
Nausea, vomiting, diarrhoea
Two studies reported on nausea, vomiting or diarrhoea, with 221/
426 events in the glycerol groups and 200/425 in the placebo
groups. The meta-analysis did not detect a difference (RR 1.09,
95%CI 0.81 to 1.47; 2 trials, 851 participants, I² = 79%, Analysis
1.5, very low-certainty evidence) but heterogeneity was high. Peltola
2007, a study conducted with children in South America, reported
more adverse events in the glycerol without steroids group (80/
148) than in the placebo group (53/148) (RR 1.51, 95% CI 1.16
to 1.96; 296 participants).
Two studies reported results that could not be added to the meta-
analysis. Sankar 2007, a study conducted with children in India,
reported that the incidence of vomiting in the glycerol and non-
glycerol groups was “similar”, and Kilpi 1995, a trial with children
conducted in Finland, reported a higher incidence of vomiting on
days 2 and 3 in the glycerol and glycerol with steroid groups (day
2: 38%, day 3: 23%) than in the steroid and placebo groups (day
2: 14%, day 3: 4%) and that vomiting led to discontinuation of
glycerol treatment in three cases.
Gastrointestinal bleeding
Overall, 10 cases (3%) of gastrointestinal bleeding were reported
in each of the glycerol and placebo groups. The meta-analysis did
not detect a difference (RR0.93, 95%CI 0.39 to 2.19; 3 trials, 607
participants, I² = 0%, Analysis 1.6, moderate-certainty evidence).
D I S C U S S I O N
Summary of main results
We included five trials evaluating glycerol in acute bacterial menin-
gitis. Other osmotic diuretics, such as mannitol and hypertonic
saline, have not yet been tested.
Glycerol was tested in adults and children with acute bacterial
meningitis in a variety of different clinical settings and in four of
the five included trials, glycerol was evaluated in a complex trial
design including dexamethasone or acetaminophen. The review
and meta-analysis did not detect an overall effect of glycerol on
mortality from acute bacterial meningitis in children and adults.
However, in the only trial in adults, glycerol was associated with
increased mortality. We assessed the quality of the evidence using
GRADE criteria as low (GRADEpro GDT 2014; Summary of
findings for the main comparison).
The meta-analysis of low-quality evidence suggested that glyc-
erol may reduce hearing loss (Summary of findings for the main
comparison).
The small numbers seen overall in the studies in children were not
sufficient to fully exclude the impact of dexamethasone, particu-
larly on neurological disabilities and deafness in children, as this
has been shown to be effective elsewhere (van de Beek 2010).
The overall number of study participants in this review was small
and a significant degree of bias was found to be present in Kilpi
1995. Analysis was mainly weighted on Ajdukiewicz 2011 and
Peltola 2007, two large studies that were both well conducted,
but limited in their population demographics and follow-up data.
Data from Peltola 2007 have been subject to systematic reviews in-
vestigating the effect of dexamethasone, and somemethodological
concerns were raised regarding the randomisation schedule (van
de Beek 2010). As a result we have assigned this study an unclear
risk of allocation bias.
Each study was undertaken in a very different environment and
the population for each has its own particular issues. The HIV
prevalence in Ajdukiewicz 2011 was 83.5% and the impact of
this on mortality and other outcomes has not been measured and
may be significant. Ajdukiewicz 2011 and Molyneux 2014 were
conducted in a severely resource-limited environment in Malawi,
with no access to advanced resuscitation or intensive care units
(UNDP 2016). All other included studies were carried out in
hospitals with intensive care units and paediatric specialist teams,
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which is not necessarily representative of most hospitals in low-
income countries. This may introduce a degree of confounding,
particularly regarding lower mortality rates in children.
Peltola 2007 was conducted at multiple sites and excluded partic-
ipants who had received parenteral antibiotics but not oral antibi-
otics before the first dose of glycerol or dexamethasone or both
glycerol and dexamethasone. The authors of Peltola 2007 did not
include these data in the analysis, so it is unclear if prior antibiotic
treatment had an effect on outcomes, particularly deafness.
The doses and duration of glycerol used varied across the included
studies, introducing further inconsistencies among studies (see
Table 2). We were unable to control for this effect in the analysis,
which may have introduced further heterogeneity (Brouwer 2011;
Saez-Llorens 2007). Prolonged use of osmotic agents, such as the
four-day courses of glycerol used in Ajdukiewicz 2011, have been
suggested to be harmful. Peltola 2007 and Sankar 2007 both used
two-day courses due to this concern. However, most seizures and
deaths in Ajdukiewicz 2011 occurred in the first two days, and
therefore an association between mortality and glycerol duration
is unlikely.
Different agents were used as placebo comparators in the studies.
Ajdukiewicz 2011 used 50% dextrose, Peltola 2007, Sankar 2007
andMolyneux 2014 used carboxymethylcellulose, and Kilpi 1995
did not use a placebo agent. It may be argued that the placebo
agents used were not wholly inert and may exert an independent
osmotic action. All trial authors designed control agents that had
a similar taste and texture to glycerol for concealment purposes,
and whether any of the substances used exerted an independent
osmotic action is untested.However, the highermortality reported
by Ajdukiewicz 2011 in the glycerol group suggests that glycerol
had an action beyond any osmotic effect exerted by the dextrose
placebo, particularly as the glycerol was diluted in dextrose for
some participants (Brouwer 2011).
The slight reduction in hearing loss observed suggests that glycerol
may be acting to reduce oedema or improve cerebral blood flow
in particular areas of the brain, either the nucleus or length of the
vestibular-cochlear nerve (which is encased in a bony canal). There
is some evidence to suggest that glycerol is required for bacterial
metabolic pathways in the central nervous system (CNS) (Mahdi
2012). Genetic susceptibility to hearing loss following meningitis
has been suggested and the presence of glycerol may attenuate the
production of free radicals that may affect CNS damage leading to
hearing loss (vanWell 2012).We selected greater than 40 dB as the
cut-off for hearing loss to capture all clinically significant deficits;
the effect of glycerol onmore severe hearing loss was not evaluated.
Currently, there are no clear data showing the mechanistic effects
of glycerol on either hearing or mortality in humans and more
research is needed. Experimental animal work has shown no effect
of glycerol in a bacterial meningitis model (Blaser 2010). The
cause of increased mortality with glycerol in adults is unclear. Risk
stratification of patients in that trial by disease severity showed
that glycerol exerted harmful effects on those patients with low
predicted risk of death on admission (Wall 2017). It is possible
that increased mortality from glycerol in these patients with a
more intact blood-brain barrier may relate to enhanced virulence
of pneumococci in the CNS in the presence of glycerol (Mahdi
2012), or harmful effects of osmotic shift across the blood-brain
barrier.
The use of dexamethasone did not have any impact on the out-
comes studied when used with or without glycerol. Other larger
reviews have found an impact of dexamethasone on the reduction
of hearing loss in children with meningitis (van de Beek 2010).
There were too few data available for analysis to inform a robust
conclusion about the utility of dexamethasone for treatment of
people with bacterial meningitis.
Overall completeness and applicability of
evidence
This is an update of aCochrane Review that examines the evidence
for the use of osmotic therapies in acute bacterial meningitis. To
date, the evidence is incomplete and unequivocal findings for the
use of glycerol for people with meningitis could not be derived.
Data from further studies are required, particularly in children, to
assess the impact of glycerol on meningitis-induced hearing loss.
There is no evidence testing any other osmotic therapy apart from
glycerol for meningitis: data from clinical studies are required. The
high-quality evidence from Ajdukiewicz 2011 demonstrates harm
from glycerol in adults with bacterial meningitis in Malawi and
no further testing or clinical use of glycerol in adults is currently
warranted.
Quality of the evidence
We assessed the quality of evidence provided by this review us-
ing the GRADE methods (Summary of findings for the main
comparison). We generally assessed the evidence as low- or very
low-quality, which indicates that further research is very likely to
change the estimates of effect.
Themain reasons for downgrading evidence quality were the small
size of the trials, the low numbers of events and the substantial
differences between locations, sizes and participant populations
studied in the included studies. Much larger trials would be nec-
essary to prove or exclude significant benefits or harms.
We also downgraded the evidence quality formortality and seizures
due to inconsistency. The only trial in adults was stopped early
due to small but statistically significant harm (Ajdukiewicz 2011),
while four trials in children did not demonstrate statistically sig-
nificant effects.
Potential biases in the review process
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Dr Katherine Ajdukiewicz is an author of this Cochrane Review
and was the principal investigator for one of the included studies.
To minimise bias she did not extract any data from her study to
include in the analysis or perform any of the analysis.
Agreements and disagreements with other
studies or reviews
There are no current systematic reviews examining glycerol or
other osmotic agents for use in acute bacterial meningitis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence to support the use of glycerol as adjunctive
treatment for acute bacterial meningitis. Glycerolmay have a small
beneficial effect on reducing deafness in surviving children but
further data are needed. Overall, the evidence quality is low.
Implications for research
Trials testing other osmotic interventions in acute bacterial menin-
gitis may be considered, particularly in children.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajdukiewicz 2011
Methods Randomised controlled trial
Participants Adults with bacterial meningitis (clinical suspicion of meningitis plus CSF evidence of
infection: > 100 white cells/mm³, predominately neutrophils, a positive gram stain or
cloudy CSF)
Interventions Oral glycerol 75 mg in 135 mL
Oral glucose 50% solution 135 mL
Outcomes Primary outcome: mortality
Secondary outcomes: epilepsy, deafness, residual neurological deficit at day 40
Notes Source of funding: the Meningitis Research Foundation
Placebo is potentially not completely inactive and 50% glucose may exert a neurological
effect in meningitis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomisation number list in blocks of 12 was pro-
duced by an independent statistician using Stata version
9.0”
Allocation concealment (selection bias) Low risk “Numbers and allocation were placed into sealed en-
velopes. Envelopes were opened sequentially by an inde-
pendent person not involved in the clinical care or assess-
ment of trial participants”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Triple blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis; all participants included in
the analysis
Selective reporting (reporting bias) Low risk None apparent
Other bias Low risk No other biases apparent
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Kilpi 1995
Methods Randomised controlled trial with 4 arms
Participants Children from 3 months to 15 years of age with bacterial meningitis (CSF culture
positive; CSF leucocytes > 100/mm²; positive blood culture in a child with signs and
symptoms of bacterial meningitis)
Interventions Glycerol 4.5 g/kg to a maximum 180 g/day divided into 3 doses/24 hours. Increased by
50% for dose 1 and decreased by 50% for dose 2. No details of placebo given. Treatment
given for 3 days
Dexamethasone 1.5 mg/kg once daily IV divided into 3 doses/24 hours. 50% dose
adjustments as per glycerol also used. Treatment given for 3 days
4 groups used, glycerol, glycerol + dexamethasone, dexamethasone and “neither”
Outcomes Primary outcome: mortality
Secondary outcomes: epilepsy, deafness, residual neurological deficit
Notes Source of funding: the Arvo and Lea Ylppö Foundation, Helsinki, Finland, and Roche
Oy, Helsinki, Finland
No details given of whether any placebo agent was used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer generated list of random ther-
apy assignments was kept at the children’s
hospital”
Allocation concealment (selection bias) Low risk “The next adjunctive treatment regimenwas
obtainable by telephone 24 hours a day”
It was not clear if this person giving the as-
signments was part of the study team or in-
dependent
Blinding (performance bias and detection
bias)
All outcomes
High risk No details of blinding were given, so we as-
sumed the study was unblinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 134 children enrolled, 12 excluded, 122 in
the final series but only 120 analysed.Details
of the missing data were not present in the
text
Selective reporting (reporting bias) High risk No details of the missing data given, so it is
not clear if selective cases are presented
Other bias Unclear risk Groups not completely matched: more fe-
males in the dexamethasone group and in-
creased meningitis due to S pneumoniae in
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Kilpi 1995 (Continued)
the control group
Molyneux 2014
Methods Randomised controlled trial with 4 arms
Participants Children aged 2 months or older with bacterial meningitis (CSF culture positive; CSF
leucocytes ≥ 100/mm² with positive blood culture; CSF ≥ 100 leukocytes with signs
and symptoms of bacterial meningitis)
Interventions 1. Glycerol + paracetamol
2. Glycerol
3. Paracetamol
4. Placebo
All placebo-controlled: carboxymethylcellulose (placebo for glycerol) and cocoa butter
base suppository (placebo for paracetamol)
Doses: glycerol 6 g/kg/day in 4 daily doses (maximum 2.5 mg/dose) for 2 days
Acetaminophen rectal suppository 35 mg/kg first dose followed by 20 mg/kg 6-hourly
for 42 hours
Outcomes Primary outcome:
• Survival to 6 months post discharge with no sequelae
Secondary outcomes:
• Sequelae that affect daily life (e.g. hemiplegia, deafness, blindness, seizures, global
developmental delay) at 6 months
• Severe incapacitating sequelae
• Death
Notes Source of funding: the Academy of Finland
In the trial registration from2008, the primary outcomes were: death, severe neurological
sequelae andhearing loss; secondary outcomeswere: audiological or neurological sequelae
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...randomisation was computer generated
in permuted blocks of 12”
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Low risk No report in trial. Email from author that
the trial was “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis; all participants
included in the analysis
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Molyneux 2014 (Continued)
Selective reporting (reporting bias) Unclear risk None apparent. Some differences between
trial report and trial registration
Other bias Unclear risk No detailed baseline characteristics: “base-
line data for the 4 groups were similar ex-
cept more children had received antibiotics
in the paracetamol + glycerol group”
Peltola 2007
Methods Randomised controlled trial with 4 arms, multicentre in South America
Participants Children aged 2 months to 16 years with bacterial meningitis (CSF culture positive,
“characteristic CSF findings” with a positive blood culture or CSF positive with latex
antigen test; symptoms and signs of bacterial meningitis with at least 3 of the following:
CSF white cell count > 1000 cells/mm³, CSF glucose < 40 mg/dL, CSF protein > 40
mg/dL, blood white cell count >15,000 cells/mm³
Interventions Glycerol 1.5 g/kg in an 85% solution divided into 3 doses/24 hours. Treatment given
for 2 days
Placebo: saline plus carboxy methylcellulose. Doses and volumes of placebo not given in
the paper
Dexamethasone 0.15 mg/kg once daily IV divided into 3 doses/24 hours. Treatment
given for 2 days
4 groups: glycerol + placebo, glycerol + dexamethasone, dexamethasone + placebo and
placebo + placebo
Outcomes Primary mortality. No secondary mortality at the end of follow-up given
Secondary outcomes: epilepsy, deafness and residual neurological deficit
Notes Source of funding: GlaxoSmithKline, AlfredKordelin, Päivikki and Sakari Sohlberg, and
Sigfrid Jusélius Funds. Farmacia Ahumada donated glycerol and both placebo prepara-
tions. Laboratorio de Chile partly donated ceftriaxone
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Stratified block randomisation took place
in blocks of 20”
Allocation concealment (selection bias) Low risk “All treatment kits were packaged accord-
ing to the randomisation lists in Santi-
ago, Chile. Saline and carboxymethylcellu-
lose were the placebo preparations for dex-
amethasone and glycerol, respectively. The
agents were provided in identical ampoules
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Peltola 2007 (Continued)
or bottles and were labelled only with a
study code”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All treatment kits were packaged accord-
ing to the randomisation lists in Santi-
ago, Chile. Saline and carboxymethylcellu-
lose were the placebo preparations for dex-
amethasone and glycerol, respectively. The
agents were provided in identical ampoules
or bottles and were labelled only with a
study code”
Incomplete outcome data (attrition bias)
All outcomes
Low risk None identified
Selective reporting (reporting bias) Low risk No missing data identified
Other bias Unclear risk Drugs were supplied by GlaxoSmithKline
(GSK) and Farmacia Ahumada. GSK par-
tially funded the study
Sankar 2007
Methods Randomised controlled trial. Single centre
Participants Children aged 2 months to 12 years with bacterial meningitis (positive CSF culture or
CSF latex agglutination positive, or CSF cytology with a suggestive biochemical profile
with fever and signs of CNS involvement)
Interventions Glycerol 1.5 g/kg IV or orally 6-hourly. Placebo carboxymethyl cellulose 2% solution
IV. Total dose of placebo not given just documented “matched”. Dexamethasone 0.15
mg/kg 6-hourly. Duration of treatment not reported
Outcomes Primary mortality. No secondary mortality at the end of follow-up given
Secondary outcomes: epilepsy, deafness and residual neurological deficit
Notes Source of funding: reported as “Nil”
This study was published twice, with a preliminary analysis of the osmotic effects pub-
lished as Singhi 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list prepared with a simple
random numbers table
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Sankar 2007 (Continued)
Allocation concealment (selection bias) Low risk Serially numbered, sealed packets prepared,
kept readily available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Clinicians and participants blinded. It was
not clear from the text if the investigators
were fully blinded but the packets were pre-
pared by a separate person from the inves-
tigating team
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were complete
Selective reporting (reporting bias) Unclear risk No data were reported for important out-
comes: adverse events and time for stop-
ping treatment
Other bias Low risk No other biases apparent
CNS - central nervous system; CSF - cerebrospinal fluid; IV - intravenous
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Almirante 1995 Case series of mannitol used for bacterial meningitis. No randomisation or placebo use documented
CTRI/2015/04/005668 RCT of newborns with bacterial meningitis receiving oral glycerol versus standard treatment. Eligible for
inclusion, but the trial was suspended. This was confirmed by the trialists
Glimåker 2014 Not a RCT: retrospectively identified controls. Osmotherapy (hypertonic saline) was one of the interven-
tions
Herson 1977 Not a RCT. Glycerol use discussed
Kumar 2014 Open-label RCT of children with raised intracranial pressure due to acute CNS infections, including
meningitis receiving fluid and vasoactive therapy to maintain cerebral perfusion pressure above 60 mm
Hg versus hyperventilation and osmotherapy to maintain intercranial pressure below 20 mm Hg
Molyneux 2015 Review article. Glycerol use discussed
Pecco 1991 Literature review and documented personal experience of the use of mannitol in meningitis
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(Continued)
Pelegrin 2012 Retrospective cohort study examining patients with bacterial meningitis 1987 to 2009 who were treated
with dexamethasone, mannitol and phenytoin. No data were collected prospectively and participants were
not randomised to receive any of the interventions
Peltola 2013 Review article. Glycerol use discussed
Singhi 2004 Review article. Not a RCT
Singhi 2007 Letter in response to the journal editorial summary of Peltola 2007
Urciuoli 1963 Mannitol tested for neurosurgical infections and not acute bacterial meningitis. Not a RCT
Vaziri 2016 Systematic review. Glycerol use discussed
CNS - central nervous system; RCT - randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Glycerol versus no osmotic diuretic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 5 1272 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.90, 1.30]
1.1 No steroids 5 853 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.90, 1.33]
1.2 With steroids 3 419 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.60, 1.74]
2 Neurological disability 5 1270 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.53, 1.00]
2.1 No steroids 5 851 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.49, 1.01]
2.2 With steroids 3 419 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.38, 1.77]
3 Seizures 4 1090 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.90, 1.30]
3.1 No steroids 4 755 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.92, 1.44]
3.2 With steroids 2 335 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.70, 1.33]
4 Hearing loss 5 922 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.44, 0.93]
4.1 No steroids 4 572 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.41, 0.99]
4.2 With steroids 3 350 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.32, 1.35]
5 Adverse effects: nausea,
vomiting, diarrhoea
2 851 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.81, 1.47]
5.1 No steroids 2 546 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.81, 1.83]
5.2 With steroids 1 305 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.66, 1.13]
6 Adverse effects: gastrointestinal
bleeding
3 607 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.39, 2.19]
6.1 No steroids 3 296 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.06, 2.60]
6.2 With steroids 3 311 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.44, 3.04]
A D D I T I O N A L T A B L E S
Table 1. Available osmotic therapies
Drug Class Mechanism of action Dose range and route Studied/used in
Glycerol Sugar alcohol Probably osmosis plus pos-
sible vascular and metabolic
benefit
IV 5% to 10% solution or
50 g
Oral 1.5 g/kg
Meningitis (Peltola 2007),
stroke (Righetti 2004)
Mannitol Sugar alcohol Osmotic diuretic IV 20% solution
1 mL/kg to 10 mL/kg or 1
g/kg
Brain trauma (Wakai 2013)
, cerebral malaria (
Namutangula 2007), stroke
(Bereczki 2007)
Sorbitol Sugar alcohol Osmotic diuretic (weak) Oral, IV Experimental brain perfu-
sion, stroke
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Table 1. Available osmotic therapies (Continued)
Hypertonic
saline
Hypertonic solutions Osmosis IV Brain trauma (Choi 2005),
stroke (Schwarz 2002)
Sodium
lactate
Hydroxy acids Osmosis (weak) IV Brain trauma (Ichai 2009)
IV: intravenous
Table 2. Comparison of included study interventions
Name of study Population Intervention and
dose
Control used Treatment
duration
Study arms
Kilpi 1995 Children in Finland Oral glycerol 4.5 g/
kg max 180 g/24 h
in 3 divided doses
Dexamethasone
(dex) 1.5mg/kgmax
60 mg/day
No oral placebo
IV saline
3 days 4 arms: IV dexam-
ethasone + glycerol,
oral glycerol, IVdex-
amethasone, neither
treatment
Sankar 2007 Children in India Oral glycerol 1.5 g/
kg 3 x daily
Dexamethasone 0.
15 mg/kg 3 x daily
Oral car-
boxymethylcellulose
2%
IV saline
Not detailed 4 arms: placebo oral
and IV, IV dexam-
ethasone + oral glyc-
erol, IV placebo +
oral glycerol, IVdex-
amethasone + oral
placebo
Peltola 2007 Children in South
America
Oral glycerol 1.5 g/
kg 3 x daily
Dexamethasone 0.
15 mg/kg 3 x daily
Oral car-
boxymethylcellulose
2%
IV saline
2 days 4 arms: oral and IV
placebo, IV dexam-
ethasone + oral glyc-
erol, IV placebo +
oral glycerol, IVdex-
amethasone + oral
placebo
Ajdukiewicz 2011 Adults in Malawi,
Southern Africa
Oral glycerol 75 mg
4 x daily diluted in
water or 50% dex-
trose solution
Oral 50% dextrose
solution
4 days Oral glycerol versus
oral 50% dextrose
Molyneux 2014 Children in Malawi,
Southern Africa
Oral
glycerol 25 mL/dose
(maximum dose) =
100 mL/24 hours.
Acetaminophen 35
mg/kg 6-hourly
Oral car-
boxymethylcellulose
2%
2 days 3 arms: oral glycerol
and oral
acetaminophen, oral
placebo and glyc-
erol,
oral acetaminophen
and oral placebo
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IV: intravenous
WH A T ’ S N E W
Last assessed as up-to-date: 17 February 2017.
Date Event Description
3 September 2017 New search has been performed We updated our searches. We included one new
trial (Molyneux 2014) and excluded six new tri-
als (CTRI/2015/04/005668; Glimåker 2014; Kumar
2014; Molyneux 2015; Peltola 2013; Vaziri 2016).
We added adverse events as an outcome and presented
death and neurological disability separately
A new author joined the team to complete this update
(Hanna Bergman)
17 February 2017 New citation required but conclusions have not
changed
Our conclusions remain unchanged.
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